1. S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503

2. Patients with heart rate ≥70 bpm HRP for interaction Primary composite endpoint Less severe heart failure (NYHA II or III and LVEF>20%) 0.82 0.854 Severe heart failure (NYHA IV and/or LVEF≤20%) 0.84 Cardiovascular death Less severe heart failure0.94 0.264 Severe heart failure0.78 Hospitalisation for worsening heart failure Less severe heart failure0.73 0.419 Severe heart failure0.83 Efficacy of ivabradine in patients according to heart failure severity Ivabradine can be safely used in severe heart failure, and may improve clinical outcomes, independently of disease severity www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503

3. Efficacy of ivabradine in patients according to heart failure severity www.shift-study.comBorer JS, et al. Am J Cardiol. 2013. 2014;113(3):497-503